Cellivery Therapeutics Inc
KOSDAQ:268600
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Intrinsic Value
Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. [ Read More ]
The intrinsic value of one Cellivery Therapeutics Inc stock under the Base Case scenario is 1 400.36 KRW. Compared to the current market price of 6 680 KRW, Cellivery Therapeutics Inc is Overvalued by 79%.
Valuation Backtest
Cellivery Therapeutics Inc
Run backtest to discover the historical profit from buying and selling Cellivery Therapeutics Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cellivery Therapeutics Inc
Current Assets | 5.7B |
Cash & Short-Term Investments | 589.8m |
Receivables | 1.8B |
Other Current Assets | 3.3B |
Non-Current Assets | 20.2B |
Long-Term Investments | 1.1B |
PP&E | 17.8B |
Intangibles | 438.8m |
Other Non-Current Assets | 957.6m |
Current Liabilities | 53.9B |
Accounts Payable | 2.9B |
Accrued Liabilities | 6.5B |
Short-Term Debt | 16.1B |
Other Current Liabilities | 28.4B |
Non-Current Liabilities | -725.6m |
Long-Term Debt | 368.7m |
Other Non-Current Liabilities | -1.1B |
Earnings Waterfall
Cellivery Therapeutics Inc
Revenue
|
22B
KRW
|
Cost of Revenue
|
-22B
KRW
|
Gross Profit
|
3.9m
KRW
|
Operating Expenses
|
-21.8B
KRW
|
Operating Income
|
-21.7B
KRW
|
Other Expenses
|
-13.6B
KRW
|
Net Income
|
-35.3B
KRW
|
Free Cash Flow Analysis
Cellivery Therapeutics Inc
KRW | |
Free Cash Flow | KRW |
Profitability Score
Profitability Due Diligence
Cellivery Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Cellivery Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Cellivery Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.
Score
Cellivery Therapeutics Inc's solvency score is 18/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Cellivery Therapeutics Inc
Shareholder Return
Price
Cellivery Therapeutics Inc
Average Annual Return | 60.58% |
Standard Deviation of Annual Returns | 135.87% |
Max Drawdown | -93% |
Market Capitalization | 244.9B KRW |
Shares Outstanding | 36 670 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).
Contact
IPO
Employees
Officers
The intrinsic value of one Cellivery Therapeutics Inc stock under the Base Case scenario is 1 400.36 KRW.
Compared to the current market price of 6 680 KRW, Cellivery Therapeutics Inc is Overvalued by 79%.